Lifecycle Management Excellence: Mature Brand Organizations and High-Performing Strategies

STUDY OVERVIEW

Increasing cost pressures are forcing pharmaceutical companies to explore sources of revenue beyond the development of new drugs. In this time- and cost-constrained environment, companies have had begun to look at lifecycle management strategies with newfound interest.

To help biopharma companies more effectively conduct the many activities related to lifecycle management, Best Practices, LLC conducted a study to provide important benchmarks on the optimal size and structure of Mature Brand Organizations. In addition, this study provides pharmaceutical and biotech executives with important benchmarks on recent barriers and regulations affecting the industry as well as the lifecycle strategies used by Mature Brand Organizations or the groups responsible for lifecycle management.

This study identifies and documents current practices and trends at Mature Brand Organizations and explores the rationale for different tactical approaches for lifecycle management strategies. In addition, the research provides insights into which strategies will survive in a changing pharmaceutical environment.

KEY TOPICS

• Barriers of Key LCM Strategies
• Strategies Weakened by Regulation or Reform
• Mature Brand Organizations
• Case Example of Pfizer's Lipitor
• Other Success Factors and Lessons Learned
  

• Technical Feasibility of Lifecycle Management Strategies Growing Mature Product
• Regulatory Feasibility of Lifecycle Management Strategies Growing Mature Product
• Cost of Lifecycle Management Strategies Growing Mature Product
• Strategies Weakened by Regulation/Reform in the next 12-24 months
• Length of time since Mature Brand Organization establishment
• Number of products MBO currently manages
• Responsibilities of Mature Brand Organization
• Regions supported by Mature Brand Organization
• Key factors governing "mature brand" status
• Major expenses of MBO Budget
  

• Global Reach: Nearly 40% of the dedicated Mature Brand groups represented in this study are focused only on the U.S. market.  The remainder of groups have additional responsibility in other countries:  62% are responsible for emerging markets, and some 40% claim responsibility countries outside developed or emerging markets (i.e., “Rest of World”). 

• Emerging Markets Least Impacted: Extending into emerging markets will be the LCM strategy least impacted by regulation/reform over the next 12-24 months.

Research participants included 25 executives and managers from 18 different pharmaceutical and biotech companies. Respondents represented more than a dozen therapeutic areas.

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.